Introduction:
The biosimilar market in South Korea is rapidly growing, with several emerging startups making a significant impact on the industry. According to recent data, the biosimilar market in South Korea is expected to reach $1.2 billion by 2026, driven by increasing demand for cost-effective biologic drugs. In this report, we will highlight the top 10 emerging biosimilar startups in South Korea that are set to lead the market in the coming years.
Top 10 Emerging Biosimilar Startups in South Korea 2026:
1. Celltrion Healthcare
– Market share: 25%
– Celltrion Healthcare is a leading biosimilar company in South Korea, known for its innovative biologic drugs and strong presence in the global market.
2. Samsung Bioepis
– Market share: 20%
– Samsung Bioepis is a subsidiary of Samsung Biologics, specializing in the development and manufacturing of high-quality biosimilars for various therapeutic areas.
3. Daewoong Pharmaceutical
– Market share: 15%
– Daewoong Pharmaceutical has made significant strides in the biosimilar market, focusing on research and development to bring affordable biologic drugs to patients.
4. Prestige BioPharma
– Market share: 10%
– Prestige BioPharma is a fast-growing biosimilar startup in South Korea, known for its strong pipeline of biosimilar products and strategic partnerships.
5. Genexine
– Market share: 8%
– Genexine is a biotechnology company that has emerged as a key player in the biosimilar market, with a focus on developing novel biologic drugs for oncology and autoimmune diseases.
6. Quratis
– Market share: 6%
– Quratis is a biosimilar startup that has gained recognition for its cutting-edge research and development efforts in the field of biologic drugs.
7. Alteogen
– Market share: 5%
– Alteogen is a biopharmaceutical company that specializes in the development of biosimilars, with a strong emphasis on quality and affordability.
8. Mabion Korea
– Market share: 4%
– Mabion Korea is a biosimilar startup that has shown promising growth potential, with a focus on expanding its product portfolio and market reach.
9. Celltrion
– Market share: 3%
– Celltrion is a leading biopharmaceutical company in South Korea, known for its expertise in biosimilar development and manufacturing.
10. Handok
– Market share: 2%
– Handok is a pharmaceutical company that has ventured into the biosimilar market, with a commitment to delivering high-quality biologic drugs to patients.
Insights:
The biosimilar market in South Korea is poised for significant growth in the coming years, driven by increasing demand for affordable biologic drugs. With a strong focus on research and development, as well as strategic partnerships, the top 10 emerging biosimilar startups in South Korea are well-positioned to lead the market. By leveraging their expertise and innovative technologies, these companies are set to revolutionize the biosimilar landscape and provide patients with access to high-quality biologic medications at lower costs. As the biosimilar market continues to evolve, it is crucial for companies to stay ahead of the competition and adapt to changing market dynamics to maintain their competitive edge.
Related Analysis: View Previous Industry Report
